New Device Announcement. The twiist™ Automated Insulin Delivery (AID) system has received clearance from FDA 510(k), although the launch date is unclear. This insulin pump has…
Generic Victoza® Teva pharmaceuticals launched a generic version of Victoza® (liraglutide injection 1.8mg ) The generic will cost $469.60 for a pack of two pens and…
In March 2023, the FDA extended the approval of Evinacumab (EVKEEZA©) to children 5-11 years with familial homozygous hypercholesteremia. Evinacumab had been previously approved for 12…
US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties. New Drugs and Therapeutics On October 26, 2023, the US…
LUPRON DEPOT-PED 45 mg for 6 months Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi…
New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved…
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)…
New Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO Update:…
Brief Therapeutic Update from PES Drugs and Therapeutics Committee iLet ® Bionic Pancreas On May 19, 2023, the U.S. Food and Drug Administration approved the…
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Sogroya® (somapactian) Once weekly Sogroya® (somapacitan-beco, Novo Nordisk) was approved by the United States Food and Drug…